Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of DFP-11207 as second-line treatment for advanced biliary tract cancer
jRCT2031250656Phase 2Recruiting
- Sponsor
- Japan Oncology Network in Hepatobiliary and Pancreas
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DFP-11207 in biliary cancer (2 arms), sponsored by Japan Oncology Network in Hepatobiliary and Pancreas. Primary endpoints: Safety and recommended dose and Progression-free survival. Started May 2026; status: recruiting.
02
Drugs
DFP-11207
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2031250656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250656.